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Abstract
Introduction: Multiple studies have shown that glial cells of the spinal cord, such as astrocytes and microglia, have
close contact with neurons, suggesting the term tripartite synapse. In these synapses, astrocytes surrounding neurons
contribute to neuronal excitability and synaptic transmission, thereby increasing nociception and thus the persistence
of chronic pain. Conversely, the N-methyl-D-aspartate (NMDA) receptor is crucial in the generation and maintenance of
chronic pain. It has multiple sites of modulation. One is the site of recognition of extracellular neurotransmitter
(glutamate), which can be blocked by competitive antagonists such as (3-(2-carboxipiperazin-4)1-propyl phosphonic
acid), (±)-CPP, resulting in a blockade of the calcium current and thus the intracellular transduction process. In the
present study, we investigated whether the potential antinociceptive effect of glial inhibition produced by
propentofylline (PPF) can be enhanced when combined with an NMDA-receptor inhibitor such as (±)-CPP.
Methods: We used Sprague-Dawley monoarthritic rats. The monoarthritis was induced by injection of complete
Freund adjuvant in the right tibiotarsal joint. Four weeks later, rats were treated with PPF (1, 10, 30, and 100 μg/10 μl)
intrathecally (i.t.) for 10 days, injected once with (±)-CPP (2.5, 5, 12.5, 25, 50, and 100 μg/10 μl, i.t.), or both treatments
combined. The antinociceptive effect was evaluated on day 11 for PPF and immediately to (±)-CPP, by assessing the
vocalization threshold to mechanical stimulation of the arthritic paw.
Results: The data indicate that intrathecal administration of increasing concentrations of (±)-CPP or PPF produced
a significant dose-dependent antinociceptive effect with respect to monoarthritic rats receiving saline. The linear
regression analysis showed that the dose that produces 30% of maximal effect (ED30) for i.t. (±)-CPP was 3.97 μg,
and 1.42 μg for i.t. PPF. The administration of the PPF and (±)-CPP combination in fixed proportions of ED30
produced a dose-dependent antinociceptive effect, showing an interaction of the supraadditive type.
Conclusions: The results suggest that glia inhibitors can synergically potentiate the effect of glutamate blockers for
the treatment of chronic inflammatory pain.
Introduction
Pain is a sensory modality that, in its acute form, performs
the physiological role of alerting the individual of real or
potential tissue damage. It is the immediate consequence
of the pain-pathways activation (nociceptive system),
ongoing in a temporal fashion, and usually resolves when
the painful stimulus is removed. Conversely, when pain
lasts, even after the lesion has been healed, or when pain is
originated without apparent tissue damage and lasts for
more than 6 months, it is considered pathologic and called
chronic pain [1].
The information collected by the nociceptors is driven
by primary afferent fibers to the spinal cord where they
synapse and transmit nociceptive information to projec-
tion neurons located in the dorsal horn of the spinal
cord. These projection neurons relay the information to
supraspinal centers through ascending pathways. The
first-order neurons release a number of neurotransmit-
ters, among others, glutamate and substance P. Substance
P stimulates NK-1 receptors that produce a slow and
prolonged depolarization in the projection neuron.
Glutamate binds to AMPA receptors, increasing depolar-
ization. When nociceptive stimulation frequency is
greater, it generates a membrane depolarization that
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triggers the release of ion Mg2+ from the NMDA recep-
tor [2], promoting the entry of Ca2+ and the subsequent
activation of the enzyme nitric oxide synthase, generating
nitric oxide production (NO). NO is a gas that diffuses
rapidly through the cell membrane and acts as an excita-
tory retrograde messenger in the neurons that generate
it, as in the presynaptic elements and adjacent astrocytes.
This event, classified as positive feedback, has an impor-
tant role in the development of synaptic neuroplasticity
mechanisms, as has been shown for hippocampal LTP [3]
and spinal potentiation known as spinal cord windup,
generated against a high and low frequency of C-fiber sti-
mulation, respectively. As a result, the perception of pain
increases significantly, a potentiation phenomenon in the
origin of the generation of chronic pain.
The NMDA receptors are tetramers [4] that can be
assembled in different configurations. The NR1 subunit
is essential for the functionality of the receptor, whereas
the NR2 subunits determine the biophysiologic proper-
ties of the channel, like the conductance and the average
time of opening or blocking sensitivity to Mg2+ [5]. The
cloning of the receptor subunits revealed that the NR1
subunit has a glycine-binding site, whereas the NR2 sub-
unit has a glutamate-binding site, which can be blocked
by competitive antagonists such as (±)-CPP, resulting in
a blockade of the Ca2+ current, and therefore the intra-
cellular transduction process, as well as the inhibition of
the windup phenomenon [6]. Moreover, a number of
other NMDAR antagonists, such as ketamine and ifen-
prodil acting on different receptor sites, have been shown
to present antinociceptive effects in models of inflamma-
tory and neuropathic pain [7-11]. This indicates that the
(±)-CPP could be used as an analgesic, because this
receptor is involved in the induction and maintenance of
central sensitization.
As mentioned earlier, the NMDA receptor is important
in the establishment of chronic pain; however, today we
know other factors that can modulate this pain, such as
glial cells [12]. In the last decade, numerous studies have
shown that glial cells of the spinal cord have a close com-
munication with neurons, proposing the term tripartite
synapse [13]. This synapse contributes to the modulation
of neuronal excitability and synaptic transmission by
increasing nociception and thus the persistence of chronic
pain. It has been found that astrocytes and microglia in
the dorsal horn of the spinal cord are active against a vari-
ety of conditions that cause chronic pain and hyperalgesia,
such as subcutaneous swelling, subcutaneous administra-
tion of inactivated mycobacterium [14], and trauma per-
ipheral nerve [15], among others [16].
Once activated glial cells release several neuroactive
molecules capable of inducing or magnifying the pain,
such as NO, prostaglandins, arachidonic acid, excitatory
amino acids (glutamate, aspartate, cysteine), quinolinic
acid, and growth factors, as well as variety of proinflam-
matory cytokines, such as interleukin-1b, interleukin-6,
and tumor necrosis factor [17]. Glial cells and neurons
have receptors for cytokines. It is accepted that cyto-
kines have a role as neuromodulators in the central ner-
vous system, specifically at the level of second-order
nociceptive neurons. In this regard, it has been reported
that IL-1b is able to increase the C-fiber response and
windup activity in the spinal cord [18] at the level of
nociceptive afferent terminals, where IL-1b increases the
release of substance P and glutamate [19].
In this context, it is apparent that the main strategy to
suppress the communication between glia and spinal
neurons is through the possibility of pharmacologically
disrupting the glial function. In this regard, different
drugs have been identified that inhibit the activity of glia,
including propentofylline (PPF) [20]. PPF has inhibitory
effects on the activity of phosphodiesterase types I, II,
and IV and on adenosine extracellular transporters in
glial cells [21], thereby modifying intracellular cyclic
nucleotide homeostasis, leading to a decrease of the pro-
duction of proinflammatory cytokines and free radicals in
these cells. This is supported by studies in which has
been found an inhibition of the release of tumor necrosis
factor and interleukin 1, as well as the formation of oxy-
gen radicals, in microglia cultures activated by LPS treat-
ment and subsequently challenged with PPF. Moreover,
increased cAMP-dependent signaling has been shown to
increase the expression of antiinflammatory cytokine
IL-10 [22]. Therefore, PPF may increase the production
of antiinflammatory cytokines and, in turn, downregu-
lates the production of proinflammatory cytokines.
PPF also functions as a reuptake inhibitor of adenosine
[23]. This is potentially important because adenosine has
been proposed to play a role in neuropathic pain. Adeno-
sine presynaptically inhibits the release of substance P
and glutamate, and postsynaptically decreases the action
of substance P and glutamate [24]. Inhibition of sub-
stance P and glutamate release can attenuate central sen-
sitization and, consequently, could decrease pain.
Because NMDA receptors and glia have an important
role in the pathophysiology of chronic pain, we propose
to evaluate whether the coadministration of (±)-CPP
and PPF could enhance the analgesic effect of each drug
on chronic inflammatory pain, by using an isobolo-
graphic analysis. The ultimate goal of drug combination
is to obtain effective analgesia with a reduction in the
incidence and severity of side effects, which can be
achieved by using lower doses of the drugs [25].
Materials and methods
Animals
In total, 152 male monoarthritic Sprague-Dawley rats
(225 to 250 g) were used in this study. The experimental
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groups were constituted by six animals in each group.
All animals were obtained from the facilities of the
Faculty of Medicine of the University of Chile, held in a
light-dark cycle of 12/12 hours, starting at 8:00 AM,
food and water ad libitum. After each experiment, rats
were killed by using an overdose of urethane (3 g/kg,
intraperitoneal, i.p.)
The experiments were conducted in accordance with
the “Guide for the Care and Use of Laboratory Animals
of National Institutes of Health (NIH)” [26] and the
rules of the International Association for the Study of
Pain (IASP) “Models of animal pain and ethics in
experimental animals” [27] and “Ethical standards in
research and management of pain.” Furthermore, the
experimental protocols were approved by the Bioethics
Committee of the Universidad de Santiago de Chile.
Induction of monoarthritis
Monoarthritic rats were used as a model of chronic
inflammatory pain. Monoarthritis was induced in rats of
120 to 150 g by the method described by Butler et al.,
[28]. In brief, rats were inoculated with a volume of 50 μl
of Freund adjuvant, in the right ankle joint. The adjuvant
consisted of a solution of 60 mg of Mycobacterium butiri-
cum, 6 ml of mineral oil, 4 ml of sodium chloride (0.9%),
and 1 ml of Tween 80. Subsequently, this mixture was
autoclaved at 120°C for 20 minutes and stored at room
temperature until use. Before injection, the solution
was homogenized by constant stirring. The injection of
adjuvant produces a localized arthritic syndrome that
becomes stable around the fourth week after inoculation,
and establishes a persistent pain with hyperalgesia of the
tibiotarsal joint, which is maintained for a period exceed-
ing 2 months. Around 90% to 95% of the injected rats
developed mechanical hyperalgesia. Monoarthritic rats
were used between the fourth and the fifth weeks after
induction of monoarthritis.
Intrathecal injection
(±)-CPP (Tocris) was administered at single doses of 2.5,
7.5, 12.5, 25, 50, and 100 μg/10 μl. PPF (Sigma) was admi-
nistered in repeated doses of 1, 10, 30, and 100 μg/10 μl,
once daily for a period of 10 days. The two drugs were
administered via i.t. injection in a volume of 10 μl and dis-
solved in saline; i.t. injection consists of administering the
drug into the subarachnoid space between lumbar verteb-
rae L5 and L6 [29], by using a Hamilton syringe with a
needle 26G × 1/2 inch’. The access to the subarachnoid
space is evidenced by a slight movement in the tail of the
rat as a result of the needle mechanical stimulation pene-
trating the meninges of the spinal cord. The daily PPF i.t.
injection was done under brief halothane anesthesia
(2 minutes).
Experimental groups
To evaluate the antinociceptive effect of both drugs
individually on monoarthritic rats, the vocalization
threshold to mechanical stimulation (Randall-Selitto
test) was used. The animals were separated in a first
stage of experimentation into two groups: (a) intrathecal
administration of (±)-CPP: 2.5, 7.5, 12.5, 25, 50, or
100 μg/10 μl (n = 6 for each dose); and (b) daily i.t.
administration of increasing PPF concentrations of 1,
10, 30, or 100 μg/10 μl (n = 8 for each dose) for 10 days.
To evaluate the antinociceptive effect of the PPF and
(±)-CPP combination, we conducted a second series of
experiments. Both drugs were diluted in decreasing
doses (1/3, 1/10, and 1/100) in relation to its ED30. Five
groups were used:
1. Daily administration of ED30 of PPF i.t. for 10 days.
At day 11, an i.t. injection of ED30 of (±)-CPP was done
(n = 6).
2. Daily administration of ED30 of PPF i.t. for 10 days.
At day 11, an i.t. injection of 1/3 of ED30 of (±)-CPP
was done (n = 6).
3. Daily administration of ED30 of PPF i.t. for 10 days.
At day 11, an i.t. injection of 1/10 of ED30 of (±)-CPP
was done (n = 6).
4. Daily administration of ED30 of PPF i.t. for 10 days.
At day 11, an i.t. injection of 1/30 of ED30 of (±)-CPP
was done (n = 6).
5. Daily administration of ED30 of PPF i.t. for 10 days.
At day 11, an i.t. injection of 1/100 of the ED30 of
(±)-CPP was done (n = 6).
Controls were provided by normal and monoarthritic
rats receiving saline, as follows:
1. Normal group of the same age of monoarthritic rats,
receiving i.t. injection of saline before testing (n = 6).
2. Monoarthritic saline group, pooled from saline con-
trols for the (±)-CPP, PPF, and combined (±)-CPP/PPF
series, receiving i.t. daily injection of saline for a period
of 10 days, followed by an i.t. injection of saline at day
11, or a single injection at day 11 (n = 16). The three
groups were pooled because they showed no significant
differences in vocalization threshold between them at
any time of testing.
Mechanical hyperalgesia
This behavioral test consists of adding a continuous and
increasing pressure with a taper ending in blunt tip on the
posterior knee joint of the rat to generate a nociceptive
behavior. The response is evidenced by a vocalization or
withdrawal reflex of the limb in response to stimulation.
The pressure on the joint is increased gradually (linearly)
up to 570 g, a value that does not harm the animal. The
equipment used for this test was called analgesiometer
Ugo Basile. Each animal was tested 2 times at 5, 15, 30,
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and 60 min for monoarthritic rats treated with (±)-CPP or
the combination of PPF and (±)-CPP, and at 15, 30, and
60 min for monoarthritic PPF-treated rats. After the
experiment, all rats were killed with an overdose of
urethane. Grams of pressure, which expresses rat nocicep-
tive behavior, were saved for later analysis. The data were
expressed as percentage change to baseline and were then
averaged over the different groups and different times.
Later, the area under the curve (AUC) was calculated, by
using the Microcal Origin V 6.0 program, and the groups
were compared statistically.
Isobolographic analysis
The evaluation of the interaction between both drugs
was performed by using isobolographic analysis [25].
The isobologram is a graphic method that consists of
calculating the theoretic additive dose for each level of
effect and their statistical comparison with the combina-
tion dose that produces the same effect experimentally.
Equieffective doses of both drugs alone are needed to
calculate the expected dose in a combination. To this
end, we determined the dose that produces 30% of max-
imal effect (ED30) by using a linear regression analysis
from the dose-response curve of six increasing doses of
(±)-CPP and the previously mentioned for increasing
doses of PPF. Once we obtained the ED30 of both drugs,
a graph was constructed by placing in the y-axis of the
ED30 point of (±)-CPP and the x-axis point of the ED30
of PPF. The union of two points by a straight line (iso-
bolo), also known as a line of additivity or no interac-
tion, helped to establish the type of interaction
(synergism or antagonism) of both compounds. The
interaction between both drugs was carried out by an
administration of 1, 1/3, 1/10, 1/30, and 1/100 of the
ED30 (±)-CPP, and PPF. The coadministration was per-
formed through intrathecal PPF ED30 daily for 10 days.
The antinociception was assessed on day 11 with the
Randall-Selitto test and then followed by i.t. administra-
tion of ED30 (±)-CPP; antinociception was assessed by
the same test. Then the ED30 of the association of both
drugs (ED30 experimental), from a dose-response curve,
was obtained by linear regression analysis. This dose
was compared statistically with the dose that theoreti-
cally represents the simple addition of effects, obtained
by the following formula:
ED30 theoretical additivity = ED30 PPF/(P1 + R∗P2)
Where R is the power ratio between the two drugs
given alone, P1 is the proportion of the drug (PPF) in
the mixture, and P2 is the proportion of drug 2
((±)-CPP) in the mixture.
The graphic region in which is located the experimen-
tal value (ED30 experimental) in relation to the theoretic
value (ED30 theoretic additivity) determines the type of
interaction: If the value is located under the line of addi-
tivity and is statistically different from the theoretic
value, the type of interaction is synergistic or supraaddi-
tive (effect greater than the sum of the individual effects
of drugs); if located next to the line of additivity and not
statistically different from the theoretic value, the inter-
action is simple additivity (equal effect of the sum of
each drug); conversely, if the experimental value lies
above the line of additivity and is statistically different
from the theoretic nature of the interaction, it is subad-
ditive or antagonistic. At the same time, we calculated
the interaction index (I.I.) between the drugs, obtained
from the following formula:
I.I. = ED30 experimental/ED30 theoretic additivity
This index, when less than 1 corresponds to a syner-
gistic interaction, when equal to 1, corresponds to an
additive interaction, and when greater than 1 is an
antagonistic interaction [30].
Statistical analysis
The results were expressed as mean percentage of anti-
nociceptive effect ± standard error of the mean (SEM)
for each experimental group, from baseline obtained
before the injection of saline or each of the drugs under
study, as appropriate. The quantification of the antinoci-
ceptive effect (%AE) of the drugs tested were calculated
as a percentage change in AUC from baseline (basal) for
each rat, and set a maximum pressure cut-off of 570 g
in the Randall-Selitto, according to the following for-
mula:
AUCpost − AUCpre = AUCdrug effect (1)
% AE = (AUCdrug effect/AUCcut-off) × 100, (2)
Where AUCpre and AUCpost are approximate integrals
of the curves obtained by the method of trapezoids and
pre-post drug injection, respectively, according to Eq. 1.
The AUCdrug effect values are the integrals of the real
effect of the drug. The antinociceptive effect (AE) was
calculated according to Eq. 2, where the AUCcut-off cor-
responds to the area of maximum pressure possible on
the animal.
To analyze the time-course of the antinociceptive
effect of increasing doses of i.t. (±)-CPP and PPF, two-
way ANOVA was performed. It allowed us to assess
both intergroup comparisons (vocalization-threshold
changes under different treatments) and intragroup
comparisons (vocalization thresholds along the time),
followed by the Bonferroni multiple comparisons test.
To analyze the percentage antinociception obtained
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from the area under the time-course curves, one-way
ANOVA was used, followed by Tukey-Kramer multiple
comparisons test. To assess differences for the theoretic
ED30 and experimental ED30, the two-tailed Student
t test was used. All statistical analyses were performed
with the Prism 3.0 software (GraphPad Software, Inc.,
San Diego CA, USA).
Results
Dose-response of (±)-CPP on mechanical nociception in
monoarthritic rats
The administration of (±)-CPP (2.5, 5, 12.5, 25, 50, or
100 μg/10 μl) increased the vocalization threshold mea-
sured at 5, 15, 30, and 60 min after injection compared
with rats receiving saline (Figure 1A), well above the
pre-monoarthritis threshold. Areas under curves indicate
that rats administered with saline showed a percentage
of antinociception of 1.1% ± 1.4%, whereas rats adminis-
tered with increasing doses of (±)-CPP showed a per-
centage of antinociception of 26.0% ± 2.4%, 33.9% ±
4.5%, 43.2% ± 5.0%, 47.8% ± 5.2%, 54.4% ± 6.8%, and
67.0% ± 6.8%, respectively (Figure 1B). In all cases, they
were significantly higher than the percentages repre-
sented by the saline, showing a dose-dependent increase
in trend. The linear regression analysis of the percentage
AE showed that the ED30 was 3.97 μg, with a 95% confi-
dence interval (95% CI) of 2.35 to 6.7 μg.
Dose-response of PPF on mechanical nociception in
monoarthritic rats
Unlike the study with (±)-CPP, the PPF was administered
over a longer term (that is, once daily for 10 consecutive
days) to ensure that the glia became inactive. At day 11
of saline or PPF treatment, the animals were challenged
with a single dose of saline (10 μl) and studied at 0, 15,
30, and 60 minutes after injection. The effect of PPF was
evaluated by comparing the treatments as independent
groups.
The administration of saline i.t. for 10 days in monoar-
thritic rats produced an average threshold of vocalization
at zero time of 174 ± 9.2 g. After the injection of saline
challenge, this vocalization threshold was unchanged at
0, 15, 30, and 60 minutes after injection (Figure 2A). In
the groups treated with 1, 10, 30, and 100 μg/10 μl PPF
for 10 days, the vocalization threshold at 0 time was
183 ± 6.3, 226 ± 13.5, 288 ± 10.0, and 310 ± 8.8 g, respec-
tively, which remained without modifications during the
60 minutes of measurement. These data show that PPF
produced dose-dependent increases in the vocalization
threshold in monoarthritic rats, the two higher doses
raising the threshold above those observed in the premo-
noarthritis condition.
Area under curves indicates that monoarthritic rats
injected with increasing doses of PPF (1, 10, 30, or
Figure 1 Antinociceptive effect of (±)-CPP in monoarthritic rats.
(A) Time-course of the antinociceptive effect of increasing doses of
i.t. (±)-CPP (2.5, 5.0, 12.5, 25, 50, and 100 μg/rat). Vocalization
thresholds were measured before (left arrow), and then 28 days
after monoarthritis induction, and after a single injection of CPP.
Open symbols, values from monoarthritic rats. Solid symbols, values
from normal rats receiving saline under a similar protocol. The right
arrow corresponds to CPP or saline injection. Values are expressed
as mean ± standard error of the mean (SEM); n = 6 rats per group.
Two-way ANOVA indicates a significant effect for the (±)-CPP
Treatment factor (F(6, 175) = 39.32; ANOVA P < 0.0001), as well as for
the Time factor (F(5, 175) = 56.64; ANOVA P < 0.0001). Bonferroni
multiple comparisons post hoc test showed that vocalization
thresholds of all (±)-CPP treated rats (2.5, 5.0, 12.5, 25, 50, and
100 μg/rat) were significantly higher (p < 0.05) than the
corresponding threshold of saline-treated animals (symbols
omitted). In addition, Bonferroni multiple comparisons post hoc test
showed that vocalization thresholds of rats after receiving the four
highest doses of (±)-CPP were significantly higher (*P < 0.05) than
the threshold measured before monoarthritis induction. (B) Ordinate
indicates percentage antinociception obtained from the area under
the time-course curves from (A) (see Materials and methods). Data
are expressed as mean ± standard error of the mean (SEM), and
were analyzed by using one-way ANOVA followed by Tukey-Kramer
multiple comparisons test (*P < 0.05; **P < 0.01; ***P < 0.001;
compared with monoarthritic rats receiving saline).
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100 μg/10 μl) showed a percentage of antinociception of
32.8% ± 1.0%, 39.4% ± 2.4%, 50.1% ± 1.8%, and 54.4% ±
1.6%, respectively (Figure 2B), which were significantly
higher than that observed in saline controls. Linear
regression analysis allowed calculation of an ED30 of
1.42 μg with a 95% CI of 0.88 to 2.27 μg.
Dose-response of the combination of PPF and (±)-CPP:
isobolographic study
In a second series of experiments, (±)-CPP and PPF
were administered together in a proportion obtained
from their respective ED30, which made possible to cal-
culate the theoretic additive dose, generating a series of
theoretic doses shown in Table 1.
In the five groups treated with increasing doses of the
PPF/(±)-CPP combination (according to Table 1), the
vocalization threshold increased for all doses, starting at
5 minutes, and remained elevated until 60 minutes after
injection (Figure 3A). For the three higher doses of the
combination, the vocalization threshold remained above
the premonoarthritis threshold throughout the testing
period.
The %AE (Figure 3B) indicates that monoarthritic rats
injected with equieffective doses of the PPF/(±)-CPP
combination showed a percentage of antinociception of
29.1% ± 5.0%, 32.1% ± 1.9%, 40.8% ± 7.9%, 36.9% ± 7.4%,
and 45.0% ± 3.6%, which were significantly higher than
that observed in saline controls. Linear regression analy-
sis showed that the ED30 for the PPF/(±)-CPP combina-
tion was 0.063 μg with a 95% CI of 0.012 to 0.334 μg.
The combined effect of both drugs was analyzed by
constructing an isobologram graph (Figure 4), which
shows that the antinociceptive activity induced by coad-
ministration of fixed proportions of the ED30 for PPF
and (±)-CPP produced a greater antinociceptive effect
than a simple additivity in monoarthritic rats. This
result is achieved because the ED30 point for the combi-
nation is under the curve of isobolo and statistically dif-
ferent from the ED30 theoretically additive, indicating
that the effect of the combination of both drugs is
supraadditive (t = 2.879; P < 0.001, two-tailed Student
Figure 2 Antinociceptive effect of PPF in monoarthritic rats.
(A) Time course of the antinociceptive effect of daily repeated
injections of PPF in monoarthritic rats. Vocalization thresholds were
measured before (left arrow), and then 28 days after monoarthritis
induction, and 10 days after repeated injection of PPF (right arrows)
(Time 0). Empty symbols represent values from monoarthritic rats.
Solid symbols represent values from normal rats receiving saline
under a similar protocol. Values are expressed as mean ± standard
error of the mean (SEM); n = 6 rats per group. Two-way ANOVA
indicates a significant effect for the PPF treatment factor (F(4, 125) =
132.20; ANOVA P < 0.0001) as well as for the time factor (F(4, 125) =
7.55; ANOVA P < 0.0001). Bonferroni multiple comparisons post hoc
test showed that vocalization thresholds of rats receiving the three
highest doses of PPF (10, 30, and 100 μg/rat) were significantly
higher (P < 0.05) than the corresponding thresholds of saline-
treated animals (symbols omitted). In addition, Bonferroni multiple
comparisons post hoc test showed that vocalization thresholds of
rats after receiving the highest doses of PPF were significantly
higher (*P < 0.05) than the threshold measured before monoarthritis
induction. (B) Ordinate indicates percentage antinociception
obtained from the area under the time-course curves from (A) (see
Materials and methods). Data are expressed as mean ± standard
error of the mean (SEM), and were analyzed by using one-way
ANOVA followed by Tukey-Kramer multiple comparisons test (***P <
0.001, compared with monoarthritic rats receiving saline).
Table 1 Fixed proportions, equieffective and theoretically
additive, used for the combination of both drugs
Fixed proportions n Equieffective
dose (μg)
Theoretically additive (μg)
PPF (±)-CPP PPF + (±)-CPP
1 6 1.42 3.97 5.39
1/3 6 0.47 1.32 1.79
1/10 6 0.14 0.4 0.54
1/30 6 0.05 0.13 0.18
1/100 6 0.01 0.04 0.05
N, number of rats.
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t test). The interaction index between PPF and (±)-CPP
was 0.024.
Discussion
The results of this study show that the analgesic effect
observed by combining PPF (a glial cells inhibitor) and
(±)-CPP (an NMDA-receptor antagonist) on the paw-
pressure test is supraadditive, in rats with chronic
inflammatory pain. The ED30 obtained for (±)-CPP was
3.97 μg, and for PPF, 1.42 μg, whereas the ED30 of the
combination was 0.063 μg, which was significantly lower
than that expected by simple additivity. The ED50 was
not used because the maximum effect of the drugs
administered separately did not exceed 60% of the maxi-
mum effect.
As pointed out elsewhere [31-34], a supraadditive
effect of combining two drugs producing the same effect
could occur only if the mechanisms of action involved
are totally or partially different (that is, “purely mutually
nonexclusive” or “partially or nonpurely nonexclusive,”
as defined by Chou [31]), but not when the mechanism
of action is the same for the two combined drugs. In
the case of combining PPF and (±)-CPP, the mechan-
isms of action are partially independent and therefore
consistent with the supraadditive effect found in the
present study.
Some evidence supports that the administration of
PPF to cultures of microglia from neonatal rat brain,
activated by lipopolysaccharides, inhibits secretion of
tumor necrosis factor (TNF-a), interleukin 1 (IL-1), and
oxygen radicals [21]. Similar results obtained from
Figure 3 Antinociceptive effect of PPF/(±)-CPP combination in
monoarthritic rats. (A) Time course of the antinociceptive effect of
daily repeated injections of PFF followed by a single injection of
(±)-CPP in monoarthritic rats. Vocalization thresholds were measured
before (left arrow) and then 28 days after monoarthritis induction,
and after 10 repeated and a single injection of PPF and (±)-CPP,
respectively (right arrows) (Time 0). Open symbols represent values
from monoarthritic rats. Solid symbols represent values from normal
rats receiving saline under a similar protocol. Values are expressed
as mean ± standard error of the mean (SEM); n = 6 rats per group.
Two-way ANOVA indicates a significant effect for the PPF/(±)-CPP
treatment factor (F(5, 180) = 51,78; ANOVA P < 0.0001) as well as for
the time factor (F(5, 180) = 44.37; ANOVA P < 0.0001). Bonferroni
multiple comparisons post hoc test showed that vocalization
thresholds of all PPF/(±)-CPP treated rats were significantly higher
(P < 0.05) than the corresponding threshold of saline-treated
animals (symbols omitted). In addition, Bonferroni multiple-
comparisons post hoc test showed that vocalization thresholds of
rats after receiving the highest doses of PPF/(±)-CPP were
significantly higher (*P < 0.05) than the threshold measured before
monoarthritis induction. (B) Ordinate indicates percentage
antinociception obtained from the area under the time-course
curves from (A) (see Materials and methods). Data are expressed as
mean ± standard error of the mean (SEM), and were analyzed by
using one-way ANOVA followed by Tukey-Kramer multiple
comparisons test (**P < 0.01; ***P < 0.001; compared with
monoarthritic rats receiving saline).
Figure 4 Isobologram for the coadministration of PPF and
(±)-CPP at fixed-ratio combinations. The white circle on the
straight line represents the point of theoretic activity calculated with
a confidence limit of 95%, whereas the black circle under the
straight line corresponds to the experimental point obtained with
the monoarthritic rats (95% confidence limit). The experimental
point was significantly different from the theoretically calculated
point (mean ± SEM; ***P < 0.001, two-tailed Student t test),
indicating supraadditive synergy in the Randall-Selitto test.
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microdialysis in the lumbar spinal cord of rats submitted
to sciatic nerve chronic constriction injury have been
reported [35]. It seems that inhibition by PPF of glial
proinflammatory cytokine secretion is mediated by the
cAMP-PKA pathway, because PPF effects are mimicked
by dibutyryl-cAMP [36], and cAMP-PKA signaling
represses proinflammatory cytokine gene expression in
microglia [37]. However, the mechanisms of action of
PPF are not yet clear. For instance, PPF has been shown
to reinstate the decreased expression of glutamate trans-
porters GLT-1 and GLAST produced for the L5 nerve
transection in mice [38], thus promoting glial glutamate
uptake and thereby glutamate excitotoxicity, therefore
decreasing nociception by a mechanism different from
proinflammatory cytokine repression. Furthermore, it
has been reported that PPF decreases hyperalgesia
induced by intracisternal BDNF administration [39],
which may constitute another different mechanism from
the previously mentioned. BDNF synthesis is increased
not only in primary afferents during chronic pain
[40,41] but also in second-order nociceptive neurons
[42,43] and glial cells [44,45] of the dorsal horn. It has
been claimed that BDNF promotes pain through two
different mechanisms: (a) by potentiating the glutama-
tergic transmission in the spinal cord via increased glu-
tamate release and enhanced synaptic efficacy at the
postsynaptic level [46], and (b) by reducing the expres-
sion of the KCC2 transporter in dorsal horn neurons,
which leads to a shift in the transmembrane anion gra-
dient that causes normally inhibitory anionic synaptic
currents to be excitatory; this latter mechanisms has
been reported to be triggered only by glial-derived
BDNF neurotrophin [44]. Because expression of the
KCC2 transporter was found to be significantly reduced
in spinal cord slices of rats with chronic inflammatory
pain [47], it is likely that in the present study, PPF could
reduce hyperalgesia by depressing glial BDNF release,
thereby restoring the normal transmembrane anion
gradient.
Conversely, it is accepted that the NMDA receptor is
crucial in the transfer of nociceptive information in the
spinal cord, specifically between the first and second
nociceptive projection neurons [48]. Studies using
antagonists of NMDA receptors have demonstrated
their effectiveness as antinociceptive drugs in animal
models of central hypersensitivity induced by cuta-
neous application of the chemical irritant mustard oil,
tested with brief electrical stimulation of the sural
nerve and challenged with MK-801 and (±)-CPP [49].
For example, MK-801 (an uncompetitive antagonist of
the NMDA receptor) prevents skin and tactile hyperal-
gesia induced by muscle noxious C-fiber stimuli [7,50],
and (±)-CPP (a competitive antagonist of the gluta-
mate-binding site on the NMDA receptor) specifically
blocks the action of glutamate, thus producing analge-
sia in different pain models [12,51]. In the present
study, we demonstrated that increasing doses of
(±)-CPP have a dose-dependent antinociceptive effects
in monoarthritic rats.
Thus, it seems clear that PPF and (±)-CPP act through
different mechanisms, but it is also clear that PPF and
(±)-CPP can functionally interact because PPF lowers
glial release of BDNF, thus avoiding the potentiating
effect of the glial-derived BDNF on the glutamatergic
transmission in the spinal cord. Therefore, the antihyper-
algesic mechanisms of action of PPF and (±)-CPP are
only partially independent, because PPF- and (±)-CPP-
dependent effects can converge at the NMDA-receptor
functionality, thus supporting supraadditive interactions
when combined in equieffective doses.
Conclusions
We showed for the first time that the glial inhibitor PPF
can synergistically potentiate the effect of (±)-CPP, a drug
that inhibits NMDA-receptor activity, thus opening the
field of associating glial inhibitors to NMDA-receptor
blockers in the pharmacologic treatment of chronic
inflammatory pain. Glial inhibitors [52,53] and NMDA
antagonists [54,55] have been associated with opioid ther-
apy in a variety of painful conditions, but glial inhibitors
and NMDA antagonists have not still assayed in combina-
tion clinical studies.
Abbreviations
ANOVA: analysis of variance; AUC: area under curve; (±)-CPP: 3-(2-
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